Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2003 4
2004 10
2005 11
2006 5
2007 11
2008 9
2009 10
2010 6
2011 8
2012 14
2013 21
2014 35
2015 46
2016 52
2017 34
2018 36
2019 68
2020 59
2021 49
2022 45
2023 36
2024 27
2025 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

522 results

Results by year

Filters applied: . Clear all
Page 1
A first-in-human phase 1/2 dose-escalation study of MAK683 (EED inhibitor) in patients with advanced malignancies.
Ribrag V, Iglesias L, De Braud F, Ma B, Yokota T, Zander T, Spreafico A, Subbiah V, Illert AL, Tan D, Santoro A, Munster PN, Suehiro Y, Wang Y, Ji DM, Chen S, Beltz K, Suenaga N, Ramkumar T, Luo F, Lai C, Wainberg ZA. Ribrag V, et al. Among authors: de braud f. Eur J Cancer. 2025 Feb 5;216:115122. doi: 10.1016/j.ejca.2024.115122. Epub 2024 Nov 16. Eur J Cancer. 2025. PMID: 39793445 Clinical Trial.
Decoding KRAS mutation in non-small cell lung cancer patients receiving immunotherapy: A retrospective institutional comparison and literature review.
Urtecho SB, Provenzano L, Spagnoletti A, Bottiglieri A, Pircher C, Massa G, Sposetti C, Proto C, Brambilla M, Occhipinti M, Mazzeo L, Beninato T, Leporati R, Giani C, Cavalli C, Serino R, Prina MM, Bassetti A, Nasca V, di Mauro RM, Abate A, Manglaviti S, Dumitrascu AD, Liberti GD, Cassano TS, Ganzinelli M, Wu S, Garassino MC, de Braud FGM, Russo GL, Prelaj A. Urtecho SB, et al. Among authors: de braud fgm. Lung Cancer. 2025 Jan;199:108051. doi: 10.1016/j.lungcan.2024.108051. Epub 2024 Dec 9. Lung Cancer. 2025. PMID: 39740426 Review.
Early downmodulation of tumor glycolysis predicts response to fasting-mimicking diet in triple-negative breast cancer patients.
Ligorio F, Vingiani A, Torelli T, Sposetti C, Drufuca L, Iannelli F, Zanenga L, Depretto C, Folli S, Scaperrotta G, Capri G, Bianchi GV, Ferraris C, Martelli G, Maugeri I, Provenzano L, Nichetti F, Agnelli L, Lobefaro R, Fucà G, Fotia G, Mariani L, Morelli D, Ladisa V, De Santis MC, Lozza L, Trecate G, Belfiore A, Brich S, Bertolotti A, Lorenzini D, Ficchì A, Martinetti A, Sottotetti E, Arata A, Corsetto P, Sorrentino L, Rediti M, Salvadori G, Minucci S, Foiani M, Apolone G, Pagani M, Pruneri G, de Braud F, Vernieri C. Ligorio F, et al. Among authors: de braud f. Cell Metab. 2025 Feb 4;37(2):330-344.e7. doi: 10.1016/j.cmet.2024.11.004. Epub 2024 Dec 17. Cell Metab. 2025. PMID: 39694040 Clinical Trial.
Exploring Genomic Biomarkers for Pembrolizumab Response: A Real-World Approach and Patient Similarity Network Analysis Reveal DNA Response and Repair Gene Mutations as a Signature.
Filetti M, Occhipinti M, Cirillo A, Scirocchi F, Ugolini A, Giusti R, Lombardi P, Daniele G, Botticelli A, Lo Russo G, De Braud F, Marchetti P, Nuti M, Ferretti E, Farina L, Rughetti A, Petti M. Filetti M, et al. Among authors: de braud f. Cancers (Basel). 2024 Nov 26;16(23):3955. doi: 10.3390/cancers16233955. Cancers (Basel). 2024. PMID: 39682144 Free PMC article.
Molecular Characterization and Clinical Relevance of MGMT-Silenced Pancreatic Cancer.
Nichetti F, Silvestri M, Agnelli L, Franza A, Pircher C, Rota S, Ambrosini P, Fotia G, Hüllein J, Randon G, Lajer P, Perrone F, Tamborini E, Leoncini G, Coppa J, Busset MDD, Pusceddu S, Milione M, Morano F, Pietrantonio F, Pruneri G, Mazzaferro V, Lipka DB, Köhler BC, Hübschmann D, Fröhling S, de Braud F, Niger M. Nichetti F, et al. Among authors: de braud f. Cancer Med. 2024 Dec;13(23):e70393. doi: 10.1002/cam4.70393. Cancer Med. 2024. PMID: 39618336 Free PMC article.
Erratum to "Unleashing precision: A review of targeted approaches in pleural mesothelioma" [Crit. Rev. Oncol./Hematol. 203C (2024) 104481].
Occhipinti M, Brambilla M, Di Liello R, Ambrosini P, Lobianco L, Leporati R, Salvarezza M, Vitiello F, Marchesi S, Manglaviti S, Beninato T, Mazzeo L, Proto C, Prelaj A, Ferrara R, Della Corte CM, Lo Russo G, de Braud F, Ganzinelli M, Viscardi G. Occhipinti M, et al. Among authors: de braud f. Crit Rev Oncol Hematol. 2024 Dec;204:104521. doi: 10.1016/j.critrevonc.2024.104521. Epub 2024 Sep 23. Crit Rev Oncol Hematol. 2024. PMID: 39317528 No abstract available.
Rogaratinib Plus Atezolizumab in Cisplatin-Ineligible Patients With FGFR RNA-Overexpressing Urothelial Cancer: The FORT-2 Phase 1b Nonrandomized Clinical Trial.
Sweis RF, Gajate P, Morales-Barrera R, Lee JL, Necchi A, de Braud F, Penel N, Grünwald V, Maruzzo M, Meran J, Ishida TC, Bao W, Zhou Y, Ellinghaus P, Rosenberg JE. Sweis RF, et al. Among authors: de braud f. JAMA Oncol. 2024 Nov;10(11):1565-1570. doi: 10.1001/jamaoncol.2024.3900. Epub 2024 Sep 19. JAMA Oncol. 2024. PMID: 39298147 Free PMC article. Clinical Trial.
Clinical and Biological Significance of HER2-Low in Ductal Carcinoma In Situ of the Breast.
Ciniselli CM, Verderio P, Baili P, Sant M, Pizzamiglio S, Duroni V, de Braud FG, Folli S, Scaperrotta G, De Santis MC, Apolone G, De Marco C, Vingiani A, Cappelletti V, Pruneri G, Di Cosimo S. Ciniselli CM, et al. Among authors: de braud fg. Clin Breast Cancer. 2025 Jan;25(1):e79-e85.e1. doi: 10.1016/j.clbc.2024.08.002. Epub 2024 Aug 8. Clin Breast Cancer. 2025. PMID: 39209598 Free article.
522 results